{
  "ticker": "BP8",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975633",
  "id": "02975633",
  "pages": 14,
  "price_sensitive": true,
  "date": "20250731",
  "time": "1830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mdnf4j7dhgr5.pdf",
  "summary": "### **Capital Raising Announcement**:  \n- **Type**: Placement  \n- **Amount Raised**: A$609,000 (before costs)  \n- **Details**: Issued 304.5M shares at A$0.002 per share (announced 28 April 2025).  \n\n### **Appendix 4C \u2013 Quarterly Cash Flow Highlights**:  \n- **Closing Cash Balance**: A$0.149M (vs. A$0.019M last quarter).  \n- **Net Operating Cash Outflow**: (A$416k) for the quarter.  \n- **Revenue from Customers**: A$89k (quarter), A$201k (YTD).  \n- **Key Payments**: R&D (A$258k), corporate costs (A$180k).  \n- **Related Party Payments**: A$56k (director remuneration).  \n\n### **Operational Highlights**:  \n1. **Commercial Sales**:  \n   - **Revenue**: A$150,646 (May\u2013June 2025) from seaweed sales, growing to A$177,316 (June\u2013July 2025).  \n   - **Offtake Agreements**:  \n     - **Kebula Partnership**: Sales to South Korea\u2019s MSC (A$95.4k export) and Indonesia\u2019s PT Surya (A$55.2k local).  \n     - **Chinese Offtake**: 2-year deal with Quanzhou Bailijie Biotech (100\u2013500 metric tons/month).  \n\n2. **R&D Developments**:  \n   - **Mineral Extraction**: Confirmed seaweed hyperaccumulates gold, silver, copper, lithium (up to 123.16 mg/kg gold). Challenges in extraction; shifting to biological methods.  \n   - **Bio-stimulants**: Partnership with Temasek Polytechnic for seaweed-based agricultural products.  \n   - **Probiotic Beverage**: R&D underway with Singapore Polytechnic.  \n\n3. **Bioremediation**: Talks with Indonesia\u2019s National Economic Council for seaweed-based coastal cleanup projects, targeting nickel/coal mining pollution.  \n\n### **Liquidity Outlook**:  \n- **Funding Runway**: **0 quarters** (cash covers <1 quarter of operating costs).  \n- **Mitigation Plans**: Reliance on growing Indonesian sales (current monthly revenue ~A$177k) and investor engagement for future capital.  \n\n**Summary**: Progress in commercial sales and R&D, but urgent need for additional funding. Material risks remain on liquidity and extraction viability.  \n\n*Note: Excluded non-material operational details (e.g., personnel appointments, facility certifications).*",
  "usage": {
    "prompt_tokens": 8551,
    "completion_tokens": 532,
    "total_tokens": 9083,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T08:59:31.400599"
}